Menopausal hormone therapy, 24-hour movement behaviours, and cardiovascular risk in postmenopausal women: a cross-sectional secondary data analysis of the WARM Hearts cohort study
Year: 2026
Type: article
Abstract: Background: Postmenopausal women face a heightened risk of cardiovascular disease (CVD) due to hormonal and aging-related physiological changes. Menopausal hormone therapy (MHT) can be prescribed to manage menopause-related symptoms, but its cardiovascular (CV) safety profile remains debated. Meanwhile, 24-hour movement behaviours such as physical activity (PA), sleep, and sedentary time are independently associated with CV risk. Few studies have examined these three movement behaviours in tandem with MHT and their relationship to CV outcomes. Objectives: (1) Replicate and extend previous work from our research group by evaluating associations between the route of unopposed estrogen MHT and CV outcomes using a larger sample size and incorporating 24-hour movement behaviours into analyses. (2) Assess whether CV outcomes differ by MHT exposures and evaluate whether movement behaviours account for more variation in CV risk than MHT usage. Methods: A cross-sectional secondary analysis was conducted using data from 929 postmenopausal women in the Women’s Advanced Risk-assessment in Manitoba (WARM) Hearts cohort. MHT exposure was classified by usage history, hormone type, and route of administration. Movement behaviours included daily moderate-to-vigorous PA (MVPA), stationary time, and sleep duration, assessed via wrist-worn accelerometry. Outcomes included measures of arterial stiffness (e.g., aortic pulse wave velocity; aPWV), blood pressure, the Framingham Risk Score (FRS), and various metabolic indicators. Group differences were assessed using ANOVA and Kruskal-Wallis tests. Hierarchical linear regression models examined associations between MHT exposures and CV outcomes, adjusting for physiological and sex and gender-related covariates. Results: Replicating our original work confirmed an association between unopposed estrogen MHT and greater aPWV and systolic blood pressure compared to vaginal use and controls. New analyses indicated that former MHT usage and oral MHT usage were associated with relatively less favourable CV outcomes compared to controls, current users, and vaginal users, particularly for aPWV and FRS. However, associations between MHT and CV outcomes were not clinically significant. In regression models, adding movement behaviours significantly improved model fit beyond MHT exposures for most CV outcomes. MVPA showed stronger associations with cardiovascular outcomes than any MHT exposure. Conclusion: MHT use does not appear to confer clinically significant CV risk in this cohort. The relationships between MHT and CV were better explained by other variables, particularly MVPA. Regardless of MHT use, postmenopausal women should focus on meeting the MVPA recommendations articulated in the Canadian 24-hour movement guidelines to promote CV health and prevent CVD.
Source: Mspace (University of Manitoba)
Author: Alexiuk, Jamie
Institution: University of Manitoba
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: hormone replacement therapy, cardiovascular risk, postmenopausal women, 24-hour movement behaviours, physical activity, sleep duration, sedentary time, arterial stiffness, pulse wave velocity, blood pressure, Framingham risk score, vaginal estrogen, oral estrogen, unopposed estrogen, accelerometry, metabolic risk factors
Open Access status: green
OpenAlex ID: W7164459421
